A new approach to treating obesity and metabolic diseases has shown promising early results in Phase I/IIa clinical trials. 

ARO-INHBE and ARO-ALK7 are investigational RNA interference (RNAi) therapeutics, developed by biotechnology company Arrowhead Pharmaceuticals. Preliminary results in Phase I/IIa trials found meaningful reductions in visceral fat, total fat and liver fat, suggesting both candidates could be effective treatments for obesity and metabolic diseases. 

ARO-INHBE showed particularly promising results, doubling weight loss and tripling reductions in visceral fat, total fat and liver fat when combined with GLP-1/GIP receptor co-agonist tirzepatide.  

“New therapeutic approaches should focus on reducing visceral fat and combining therapies to achieve a low cardiovascular risk state and improve cardio-renal-metabolic outcomes,” said Carel le Roux, Chair in Chemical Pathology and Metabolic Medicine at University College Dublin School of Medicine. 

“The interim clinical trial results announced today for Arrowhead’s ARO-INHBE and ARO-ALK7 show dramatic and rapid reductions in visceral fat, a key driver in metabolic diseases. Furthermore, ARO-INHBE in combination with tirzepatide almost doubled weight loss and improved multiple measures of body composition versus tirzepatide alone in patients with obesity and type 2 diabetes mellitus.  

“This is promising and demonstrates therapeutic potential for RNAi-based targeting of the Activin E/ALK7 pathway directly in a patient population that typically loses less weight on therapy and experiences worse cardiovascular outcomes compared to non-diabetic patients. This is a clear area of high unmet need.” 

Targeting the Activin E/ALK7 pathway could address care ‘limitations’

The clinical trial results also represent the first in-human demonstration that the Activin E/ALK7 pathway, a genetically validated pathway that regulates adipose fat storage, may potentially be harnessed therapeutically to improve body composition and enhance weight loss. 

“While incretin-based therapies have meaningfully advanced the treatment of obesity and metabolic disease, shortcomings around loss of lean mass, tolerability related to GI effects, reduced response in patients with diabetes, and disproportional fat mass gain after cessation of therapy remains a challenge for many patients,” added James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead. 

“Interim results from the Phase I/IIa studies of ARO-INHBE and ARO-ALK7 provide encouraging early evidence that targeting the Activin E/ALK7 pathway may address some of the limitations in current standard-of-care obesity treatments.” 

 

Bruno Quinney, Content Team, DDW